Education
About Us
Working with TipRanks
Follow Us
Neovacs SA (FR:ALNEV)
:ALNEV
ALNEV Stock Chart & Stats
€0.01
-€0.06(-6.03%)
At close: 4:00 PM EST
€0.01
-€0.06(-6.03%)
Day’s Range― - ―
52-Week Range€0.01 - €1,800.00
Previous CloseN/A
Volume950.00
Average Volume (3M)1.46M
Market Cap
€763.00
Enterprise Value-€204.31K
Total Cash (Recent Filing)€435.45K
Total Debt (Recent Filing)€230.37K
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Mar 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.11
Shares Outstanding476,625
10 Day Avg. Volume1,456,964
30 Day Avg. Volume1,459,251
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)9.86
Price to Sales (P/S)485.89
P/FCF Ratio-48.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Kinoid PlatformOwning the Kinoid immunotherapy platform is a durable strategic asset: it can be applied across multiple autoimmune indications, reduces single-product risk, and supports long-term licensing or co-development deals, strengthening future revenue diversification.
Low Financial LeverageMinimal debt reduces solvency risk and preserves strategic flexibility over months: the company can pursue partnership deals, asset sales, or raise capital without heavy interest burdens, important for a biotech with multi-year R&D timelines.
Partnership-driven Monetization ModelA business model centered on collaborations, milestones and royalties offers non-dilutive or staged funding and aligns incentives with larger pharma partners. Over 2-6 months this reduces capital intensity for commercialization and preserves cash runway relative to solo commercialization.
Bears Say
Declining Revenues And Negative MarginsSustained revenue decline and persistently negative margins indicate weak commercial traction and poor operational scalability. Over time this undermines ability to fund trials, attract partners on favorable terms, and makes reaching sustained profitability a material structural challenge.
Persistent Negative Operating Cash FlowOngoing negative operating and free cash flow forces reliance on external funding and increases execution risk. Structurally, this limits discretionary R&D spending, heightens dilution or financing needs, and can delay clinical programs absent durable funding sources.
Erosion Of Equity And Asset BaseA shrinking equity and asset base reduces the firm's financial cushion and borrowing capacity. Over a multi-month horizon this weakens resilience to development setbacks, constrains strategic options, and increases the likelihood of dilutive financings if improvements aren't realized.
Neovacs SA News
ALNEV FAQ
What was Neovacs SA’s price range in the past 12 months?
Neovacs SA lowest stock price was €0.01 and its highest was €1800.00 in the past 12 months.
What is Neovacs SA’s market cap?
Neovacs SA’s market cap is €763.00.
When is Neovacs SA’s upcoming earnings report date?
Neovacs SA’s upcoming earnings report date is Mar 30, 2026 which is in 42 days.
How were Neovacs SA’s earnings last quarter?
Neovacs SA released its earnings results on Oct 23, 2025. The company reported -€5.11 earnings per share for the quarter, missing the consensus estimate of N/A by -€5.11.
Is Neovacs SA overvalued?
According to Wall Street analysts Neovacs SA’s price is currently Overvalued.
Does Neovacs SA pay dividends?
Neovacs SA does not currently pay dividends.
What is Neovacs SA’s EPS estimate?
Neovacs SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neovacs SA have?
Neovacs SA has 476,625 shares outstanding.
What happened to Neovacs SA’s price movement after its last earnings report?
Neovacs SA reported an EPS of -€5.11 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.458%.
Which hedge fund is a major shareholder of Neovacs SA?
Currently, no hedge funds are holding shares in FR:ALNEV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neovacs SA
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.